Navigation Links
Deadline Approaching for UCB Rheumatoid Arthritis Family Scholarship
Date:3/5/2010

ATLANTA, March 5 /PRNewswire/ -- Applications are being accepted until March 19, 2010 for the UCB Rheumatoid Arthritis Family Scholarship. These scholarships are for rheumatoid arthritis patients or their immediate family members. Winners are awarded up to $10,000 to continue their studies at an accredited institution of higher education in the U.S.

Requirements and an application can be found at http://www.reachbeyondra.com/scholarship. UCB awards more than 100 scholarships each year to patients suffering from a variety of diseases including epilepsy, Crohn's disease and rheumatoid arthritis.

About The UCB Rheumatoid Arthritis Family Scholarship

The program is designed for applicants of any age. Applicants must be legal and permanent residents of the United States; diagnosed with RA by a physician; seeking an associate's, undergraduate, or graduate degree or enrolled in a trade school educational program; enrolled in or awaiting acceptance from a United States-based institution of higher education; and a student who demonstrates academic ambition and embraces a way of life that overcomes the boundaries of living with RA.

About UCB

UCB (http://www.ucb.com) is a biopharmaceutical company dedicated to the research, development and commercialization of innovative medicines with a focus on the fields of central nervous system and immunology disorders. UCB employs approximately 10,000 people in 40 countries.

Further Information:

Bert Kelly, UCB U.S. Communications & Public Relations, 770.970.8491, or e-mail: bert.kelly@ucb.com

This release was issued through eReleases(TM).  For more information, visit http://www.ereleases.com.

SOURCE UCB

Back to top

RELATED LINKS
http://www.ucb.com

'/>"/>

SOURCE UCB
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Mosquito Season Approaching: American Heartworm Society Reminds Pet Owners of Risk
2. CEL-SCI Study Shows CEL-2000 Vaccine Blocks Progression of Rheumatoid Arthritis
3. Enbrel Will Remain Decision Resources Clinical Gold Standard Through 2018 for the Treatment of Rheumatoid Arthritis
4. ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis
5. New Market Research Report from BioTrends Provides Insight on How Rheumatologists are Utilizing Biologic Agents in the Treatment of Rheumatoid Arthritis
6. Ninety Eight Percent of Surveyed Rheumatologists Will Prescribe Roches Actemra for Rheumatoid Arthritis
7. SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector
8. Phytomedics Inc. Announces Publication of the Phase 2b Clinical Trial Results of an Extract of the Chinese Herbal Remedy Tripterygium wilfordii Hook F in Rheumatoid Arthritis
9. Rigels R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial
10. Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi2 Clinical Trial of R788 in Rheumatoid Arthritis
11. Thiarabine Demonstrates a Reduction of Both Inflammatory and Erosive Disease Parameters in Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... Research and Markets has announced the ... Strategies" report to their offering. ... Pain Management in the ... their physical pain, emphasizing consumer survey analysis, including trends over ... adults who have selected illnesses/conditions strongly associated with physical pain ...
(Date:3/24/2017)... 24, 2017 ShangPharma, a leading ... cost-effective drug development and discovery services, technology, ... industry, announced today the intent for a ... be consolidating the Contract Research Organizations (CRO) ... ChemPartner. These entities include ChemPartner Shanghai, ChemPartner ...
(Date:3/24/2017)... , Mar. 24, 2017 Research and Markets ... Pipeline Analysis, 2016" report to their offering. ... The IPF pipeline is very strong with a ... Merck & Co., Inc., Biogen and Sanofi are involved in the development ... of which one is in Phase III stage, 15 are in Phase ...
Breaking Medicine Technology:
(Date:3/23/2017)... ... March 23, 2017 , ... The physicians of KSF Orthopaedic Center ... Houston Area. The new location is located at 2255 E. Mossy Oaks Rd., Suite ... This newest location will provide patients living in the north Houston area (The Woodlands, ...
(Date:3/23/2017)... ... March 23, 2017 , ... Texas Physical Therapy ... 960 Gruene Road in Building 2. The clinic is the group’s second in New ... says opening the company’s second New Braunfels location brings things full circle for the ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... The IoT ... and WiFi connectivity are making a huge impact on businesses and individual consumers alike. ... estimates the IoT will have a value anywhere from $4 trillion to $11 trillion ...
(Date:3/23/2017)... ... ... of adults are unaware of the dangers that infectious bacteria play in mouth disease, while ... a day that dentists recommend. The ramifications of improper oral upkeep go far beyond bad ... 164 million hours of work each year due to dental issues. That is why Mediaplanet ...
(Date:3/23/2017)... ... ... March is National Kidney Month – the perfect time to pause and ... health. Every day, two kidneys filter about 120 to 150 quarts of blood. Put ... waste, regulating fluid levels and blood pressure, supporting bone health and promoting red blood ...
Breaking Medicine News(10 mins):